शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
KOPRANNSEKopran Limited· PharmaceuticalsHighNeutral
Announced Tue, 29 Jul, 2025 · 14:30 IST

Kopran Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue declinedEBITDA margin compressionResults View source PDFExplain this filing

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.7%Reaction day
₹176.51
prior close
₹170.59
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.5%-6.2% vs market

On the reaction day the stock moved 6.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
-2.5
15m
-1.8
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-4.7+1.5-6.2
Next day
-6.0+1.8-7.8
2d
-9.0+1.1-10.1
3d
-9.9-0.5-9.4
4d
-7.3+0.0-7.4
5d
-9.3-0.3-9.0
1w
-10.5-1.7-8.8
15d
-8.4+0.1-8.6
1m
-12.6-2.9-9.8
2m
-3.1-3.0-0.2
3m
-5.3+1.0-6.4
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kopran Limited reported its unaudited Q1 FY26 results with consolidated revenue from operations at Rs. 13,521.62 lakhs, down about 3% from Rs. 13,943.65 lakhs in Q1 FY25. Consolidated profit after tax fell sharply to Rs. 744.93 lakhs from Rs. 1,109.54 lakhs, a drop of nearly 33%, with EPS declining from Rs. 2.30 to Rs. 1.54. On a standalone basis, revenue rose modestly to Rs. 5,133.48 lakhs from Rs. 4,960.70 lakhs, but standalone PAT slipped to Rs. 351.81 lakhs from Rs. 424.59 lakhs. EBITDA margin (PBT plus finance cost plus depreciation, divided by total income) compressed from around 14.6% to 12.1% on a consolidated basis. Statutory auditor Khandelwal Jain & Co. issued an unmodified review opinion. Separately, the board appointed Mr. Chandresh Gandhi as an independent director, named Mr. Surendra Somani as Chairman & Managing Director effective January 1, 2026, accepted the resignation of Chairman Mr. Susheel Somani citing ill health, and appointed M/s Smita Prabhu & Associates as secretarial auditor for five years. The 66th AGM is scheduled for September 11, 2025.

Likely market impact

Mixed-to-weak quarter for shareholders: top line dipped and profits fell sharply on a consolidated basis, which may pressure the stock in the near term despite a clean auditor review. Leadership transition with Surendra Somani moving from Executive Vice-Chairman to Chairman & MD brings continuity but the resignation of long-time Chairman Susheel Somani on health grounds adds a layer of uncertainty at the top.